A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis

• Status: Completed
• Trial end date: 2008-02-01
• Target enrollment: 0
• Participant gender: All

Summary

A double-blind, placebo-controlled, randomized, parallel-group study to evaluate the activity of oral AB1010 in adults patients with moderate to severe chronic plaque psoriasis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AB Science

Criteria

Inclusion Criteria:

• Male or female outpatients aged 18 to 75 years with chronic plaque psoriasis

• Plaque psoriasis covering ≥ 10% BSA

• Disease duration ≥ 6 months

• PASI ≥ 12.0 at screening

Exclusion Criteria:

• Guttate, erythrodermic or pustular psoriasis as sole or predominant form of the disease

• Clinically significant psoriasis flare during screening or at time of enrollment

• Systemic therapy for psoriasis or systemic immunosuppressive therapy for other indications within 28 days prior to enrollment

• Topical treatment for psoriasis within 14 days prior to enrollment

• Use of CYP3A4 moderate and strong inhibitors within 4 weeks prior to randomization

• Active current bacterial, viral (including hepatitis B and C, HIV, EBV, CMV, herpes zoster, herpes simplex), fungal, mycobacterium, protozoan, or other infection